

budesonide inhaler 100mcg, 200mcg, 400mcg (Easyhaler[®] Budesonide)

Ranbaxy (UK) Ltd

(No.241/06)

Product Update

10 February 2006

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

budesonide inhaler (Easyhaler[®] Budesonide) is accepted for use within NHS Scotland for the treatment of mild, moderate or severe persistent asthma in adults and children over 6 years of age.

Easyhaler[®] Budesonide offers an alternative to existing dry powder inhaled formulations of budesonide at a reduced cost.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the New Drugs Committee and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 05 December 2005.

**Chairman,
Scottish Medicines Consortium**